AMGN
AMGEN INC
NASDAQ · Healthcare · Drug Manufacturers - General · US
$385.65
+1.55%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- $5.79
- Revenue estimate
- $10.0B
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- $6.29
- EPS estimate
- $5.62
- Revenue actual
- $10.1B
- Revenue estimate
- $9.4B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 12
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +11.6%
- Revenue beats (12Q)
- 8
Analyst ratings
Sell-side consensus
- Consensus
- Hold
- Price target
- $400
- PT range
- $230 – $460
- Analysts
- 23
9 Buy12 Hold2 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | $5.62 | $6.29 | Beat 11.92% | $10.1B |
| Apr 30, 2026 | $4.77 | $5.15 | Beat 7.97% | $8.6B |
| Feb 3, 2026 | $4.73 | $5.29 | Beat 11.84% | $9.9B |
| May 1, 2025 | $4.27 | $4.90 | Beat 14.75% | $8.1B |
| Feb 4, 2025 | $5.04 | $5.31 | Beat 5.36% | $9.1B |
| May 2, 2024 | $3.88 | $3.96 | Beat 2.06% | $7.4B |
| Feb 6, 2024 | $4.59 | $4.71 | Beat 2.61% | $8.2B |
| Oct 31, 2023 | $4.65 | $4.96 | Beat 6.67% | $6.9B |
| Aug 3, 2023 | $4.44 | $5.00 | Beat 12.61% | $7.0B |
| Apr 27, 2023 | $3.85 | $3.98 | Beat 3.38% | $6.1B |
| Jan 31, 2023 | $4.04 | $4.09 | Beat 1.24% | $6.8B |
| Nov 3, 2022 | $4.44 | $4.70 | Beat 5.86% | $6.7B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026